RenovoRx (NASDAQ:RNXT) Now Covered by HC Wainwright

HC Wainwright assumed coverage on shares of RenovoRx (NASDAQ:RNXT) in a report released on Thursday,Benzinga reports. The firm issued a buy rating and a $3.00 price objective on the stock.

Separately, Ascendiant Capital Markets lifted their target price on shares of RenovoRx from $8.25 to $9.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th.

RenovoRx Stock Performance

Shares of RNXT stock opened at $1.02 on Thursday. The firm has a market capitalization of $24.48 million, a price-to-earnings ratio of -1.79 and a beta of 1.15. The business’s 50-day moving average price is $1.13 and its 200-day moving average price is $1.15. RenovoRx has a 12 month low of $0.77 and a 12 month high of $1.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new stake in shares of RenovoRx in the fourth quarter valued at about $49,000. Renaissance Technologies LLC bought a new stake in RenovoRx in the fourth quarter valued at approximately $84,000. Finally, Geode Capital Management LLC increased its position in RenovoRx by 61.9% during the 3rd quarter. Geode Capital Management LLC now owns 232,937 shares of the company’s stock valued at $247,000 after purchasing an additional 89,018 shares during the period. 3.10% of the stock is owned by institutional investors and hedge funds.

About RenovoRx

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.